Alto Neuroscience (ANRO) Payables (2023 - 2026)
Alto Neuroscience (ANRO) posted Payables of $3.4 million for Q1 2026, up 79.39% sequentially from $1.9 million in Q4 2025, and up 143.42% YoY from $1.4 million in Q1 2025.
Alto Neuroscience (ANRO) Payables (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Payables for 4 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Payables rose 143.42% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 143.42% YoY) and the FY2025 annual result came in at $1.9 million, up 18.94% from the prior year.
- Payables rose to $3.4 million in Q1 2026 per ANRO's latest filing, from $1.9 million in the prior quarter.
- Over five years, Payables peaked at $3.4 million in Q1 2026 and troughed at $1.1 million in Q4 2023.
- A 4-year average of $2.0 million and a median of $1.9 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2025 and 2026: Payables plunged 42.62% in 2025, then surged 143.42% in 2026.
- Over 4 years, Payables stood at $1.1 million in 2023, then jumped by 47.02% to $1.6 million in 2024, then advanced by 18.94% to $1.9 million in 2025, then surged by 79.39% to $3.4 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $3.4 million, $1.9 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.02 Mn |
| Mar 31, 2026 | 3.37 Mn |
| Dec 31, 2025 | 1.88 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Sep 30, 2024 | 2.25 Mn |
| Jun 30, 2024 | 1.84 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | 1.07 Mn |